Literature DB >> 32055593

Estimated glomerular filtration rate, anemia and outcomes in patients with ischemic stroke.

Huihui Liu1, Huaguang Zheng2,3, Peng Wu4, Chun-Feng Liu1, David Wang5, Hao Li2,3, Xia Meng2,3, Yongjun Wang2,3, Yongjun Cao1, Yilong Wang2,3, Yuesong Pan2,3.   

Abstract

BACKGROUND: Anemia is highly prevalent in patients with low estimated glomerular filtration rate (eGFR). However, the combined effect of anemia and low eGFR on the prognosis of stroke has not been well studied.
METHODS: Data of patients with acute ischemic stroke in the prospective cohort study of China National Stroke Registry was reviewed. According to the levels of eGFR and hemoglobin, patients were categorized into four groups: low eGFR (<60 mL/min per 1.73 m2) or normal eGFR (≥60 mL/min per 1.73 m2) with or without anemia. Multivariate logistic regression methods were used to analyze the association between eGFR with or without anemia and outcomes after stroke [the poor functional outcome (modified Rankin Scale, mRS 3-6), mortality and stroke recurrence] at 3 months and 1 year.
RESULTS: This study included 8,303 stroke patients. After adjusting for the confounding factors, low eGFR with normal hemoglobin increased the risk of mortality at 1 year of follow-up [odds ratio (OR) =1.50; 95% confidence interval (95% CI), 1.14-1.97]. Anemia with normal eGFR was not associated with any poor outcome at 1-year of follow-up. In patients with both low eGFR and anemia, there was an increased risk of 1-year poor functional outcome (OR 1.73; 95% CI, 1.30-2.29), mortality (OR 2.64; 95% CI, 1.94-3.59) and stroke recurrence (OR 1.42; 95% CI, 1.06-1.91). Combined and interactive effects of the pattern of low eGFR and anemia on the poor functional outcome (P for interaction =0.02) and all-cause mortality (P for interaction =0.046) were observed.
CONCLUSIONS: Ischemic stroke patients with concurrent low eGFR and anemia increased risks of poor functional outcome, mortality and stroke recurrence after 1-year follow-up. 2020 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Kidney function; anemia; outcomes; stroke

Year:  2020        PMID: 32055593      PMCID: PMC6995746          DOI: 10.21037/atm.2019.11.148

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  25 in total

1.  GFR estimating equations in a multiethnic Asian population.

Authors:  Boon Wee Teo; Hui Xu; Danhua Wang; Jialiang Li; Arvind Kumar Sinha; Borys Shuter; Sunil Sethi; Evan J C Lee
Journal:  Am J Kidney Dis       Date:  2011-05-20       Impact factor: 8.860

2.  In vivo evidence that erythropoietin protects neurons from ischemic damage.

Authors:  M Sakanaka; T C Wen; S Matsuda; S Masuda; E Morishita; M Nagao; R Sasaki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

3.  Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study.

Authors:  Jerome L Abramson; Claudine T Jurkovitz; Viola Vaccarino; William S Weintraub; William McClellan
Journal:  Kidney Int       Date:  2003-08       Impact factor: 10.612

4.  Chronic kidney disease and clinical outcome in patients with acute stroke.

Authors:  Gilad Yahalom; Roseline Schwartz; Yvonne Schwammenthal; Oleg Merzeliak; Maya Toashi; David Orion; Ben-Ami Sela; David Tanne
Journal:  Stroke       Date:  2009-01-29       Impact factor: 7.914

5.  Predictive value of routine hematological and biochemical parameters on 30-day fatality in acute stroke.

Authors:  R S Bhatia; R K Garg; S P S Gaur; A M Kar; R Shukla; A Agarwal; R Verma
Journal:  Neurol India       Date:  2004-06       Impact factor: 2.117

6.  Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial.

Authors:  Tzu-Hsien Tsai; Cheng-Hsien Lu; Christopher Glenn Wallace; Wen-Neng Chang; Shu-Feng Chen; Chi-Ren Huang; Nai-Wen Tsai; Min-Yu Lan; Pei-Hsun Sung; Chu-Feng Liu; Hon-Kan Yip
Journal:  Crit Care       Date:  2015-02-25       Impact factor: 9.097

Review 7.  Impact of Hemoglobin Levels and Anemia on Mortality in Acute Stroke: Analysis of UK Regional Registry Data, Systematic Review, and Meta-Analysis.

Authors:  Raphae S Barlas; Katie Honney; Yoon K Loke; Stephen J McCall; Joao H Bettencourt-Silva; Allan B Clark; Kristian M Bowles; Anthony K Metcalf; Mamas A Mamas; John F Potter; Phyo K Myint
Journal:  J Am Heart Assoc       Date:  2016-08-17       Impact factor: 5.501

8.  Post-Glucose Load Measures of Insulin Resistance and Prognosis of Nondiabetic Patients With Ischemic Stroke.

Authors:  Yuesong Pan; Jing Jing; Weiqi Chen; Huaguang Zheng; Qian Jia; Donghua Mi; Hao Li; Xingquan Zhao; Liping Liu; Chunxue Wang; Herbert Y Gaisano; Yan He; Yilong Wang; Yongjun Wang
Journal:  J Am Heart Assoc       Date:  2017-01-20       Impact factor: 5.501

9.  Hemoglobin concentration does not impact 3-month outcome following acute ischemic stroke.

Authors:  Kartavya Sharma; Daniel J Johnson; Brenda Johnson; Steven M Frank; Robert D Stevens
Journal:  BMC Neurol       Date:  2018-06-02       Impact factor: 2.474

10.  Association of anemia and hemoglobin decrease during acute stroke treatment with infarct growth and clinical outcome.

Authors:  Sebastian Bellwald; Rupashani Balasubramaniam; Michael Nagler; Meret S Burri; Samuel D A Fischer; Arsany Hakim; Tomas Dobrocky; Yannan Yu; Fabien Scalzo; Mirjam R Heldner; Roland Wiest; Marie-Luise Mono; Hakan Sarikya; Marwan El-Koussy; Pasquale Mordasini; Urs Fischer; Gerhard Schroth; Jan Gralla; Heinrich P Mattle; Marcel Arnold; David Liebeskind; Simon Jung
Journal:  PLoS One       Date:  2018-09-26       Impact factor: 3.240

View more
  1 in total

1.  Association between aspirin-induced hemoglobin decline and outcome after acute ischemic stroke in G6PD-deficient patients.

Authors:  Yicong Chen; Jianle Li; Zilin Ou; Yusheng Zhang; Zhijian Liang; Weisheng Deng; Weixian Huang; Fubing Ouyang; Jian Yu; Shihui Xing; Jinsheng Zeng
Journal:  CNS Neurosci Ther       Date:  2021-08-08       Impact factor: 5.243

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.